Renal Response Outcomes of the EuroLupus and National Institutes of Health Cyclophosphamide Dosing Regimens in Childhood‐Onset Proliferative Lupus Nephritis
Main finding · Complete renal responseResult — go to the resultOdds ratio 0.76 95% CI 0.29–1.98Authors' conclusion
Our study failed to demonstrate a benefit of the NIH regimen over the EuroLupus CYC regimen in childhood-onset proliferative LN.
Study context
- Population
- Patients with childhood-onset proliferative lupus nephritis (LN) treated with CYC at 11 pediatric centers in North America
- Participants
- 145 patients
- Exposure
- EuroLupus vs National Institutes of Health (NIH) CYC regimen
- EuroLupusn = 58
- NIHn = 87reference
- Outcome
- Complete renal response (contrast between CYC regimens at 12 months)
- Follow-up
- 12 months
Methodological detailsmulticentre (11 pediatric centers, North America), generalized estimating equations with a logit link, multivariable adjustment
- Multicentre (11 pediatric centers, North America)
- Generalized estimating equations with a logit link
- Multivariable adjustment
Main finding
Complete renal response
Odds ratio
0.76
95% CI 0.29–1.98
EuroLupusvs NIH
OR 0.76 (95% CI 0.29–1.98)
As reported in the abstract
Observational data: associations, not effects.
Further findings
| Outcome | OR (95% CI) | |
|---|---|---|
| At least partial renal response · 12 months | 1.35 (0.57–3.19) | |
| 0.20.5125Odds ratio (log scale) |
Original publication
Renal Response Outcomes of the EuroLupus and National Institutes of Health Cyclophosphamide Dosing Regimens in Childhood‐Onset Proliferative Lupus Nephritis. Arthritis Rheumatol. Published 11 January 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →